Goldman Sachs
OGEN icon

Goldman Sachs’s Oragenics OGEN Stock Holding History

Goldman Sachs’s Portfolio OGEN Stock Details OGEN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-2
Closed -$14K – 6792
2017
Q2 		$14K Hold
2
– – ﹤0.01% 6614
2017
Q1 		$17K Hold
2
– – ﹤0.01% 6543
2016
Q4 		$21K Sell
2
-1
-33% -$9.28K ﹤0.01% 6631
2016
Q3 		$23K Buy
3
+2
+200% +$24K ﹤0.01% 6713
2016
Q2 		$7K Buy
+1
New +$13.4K ﹤0.01% 6901

Other funds holding OGEN

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
GC
Guggenheim Capital Chicago, Illinois $12.9B AUM 27.3% 1-Year Est. Return

Goldman Sachs's OGEN Position: Q3 2017 in Review

Goldman Sachs sold out of Oragenics (OGEN) in Q3 2017, closing a stake of 2 shares — an estimated $14K sold.

Goldman Sachs first reported a position in OGEN in Q2 2016 and held it in 5 quarters. The position peaked at $23K in Q3 2016. 11 funds tracked by Wall St. Rank hold OGEN as of Q3 2017.

  • Goldman Sachs reported no remaining Oragenics position as of Q3 2017 after selling out during the quarter.
  • Goldman Sachs sold 2 Oragenics shares in Q3 2017, an estimated $14K.
  • Goldman Sachs first reported a position in Oragenics in Q2 2016 and held it in 5 quarters.
  • Goldman Sachs's Oragenics position peaked at $23K in Q3 2016.
  • 11 funds tracked by Wall St. Rank held Oragenics as of Q3 2017.

Based on Goldman Sachs's 13F filing for Q3 2017, filed 14 Nov 2017.